论文部分内容阅读
目的探讨伊立替康应用于转移性结直肠癌的临床疗效。方法 46例转移性结直肠癌的患者,所有患者均未经放疗和化疗,将患者随机分为治疗组和对照组,每组23例。治疗组给予伊立替康+奥沙利铂+亚叶酸方案。对照组给予奥沙利铂+5-氟尿嘧啶+亚叶酸方案,比较两组患者的临床疗效及两组患者的生存情况。结果治疗组的总有效率(60.9%)明显高于对照组(30.4%),两组比较差异有统计学意义(P<0.05);治疗组的总生存情况明显高于对照组,差异具有统计学意义(P<0.05)。结论伊立替康治疗转移性结直肠癌,临床效果显著,可供临床参考与应用。
Objective To investigate the clinical efficacy of irinotecan in metastatic colorectal cancer. Methods 46 cases of metastatic colorectal cancer patients, all patients without radiotherapy and chemotherapy, the patients were randomly divided into treatment group and control group, 23 cases in each group. The treatment group was given irinotecan + oxaliplatin + leucovorin regimen. The control group was given oxaliplatin + 5- fluorouracil + leucovorin program, and the clinical efficacy and survival of the two groups were compared. Results The total effective rate (60.9%) in the treatment group was significantly higher than that in the control group (30.4%), the difference between the two groups was statistically significant (P <0.05); the overall survival in the treatment group was significantly higher than that in the control group Significance (P <0.05). Conclusion The irinotecan treatment of metastatic colorectal cancer, the clinical effect is significant, for clinical reference and application.